Commercialisation of an imaging based dementia diagnostic test in the Chinese market - feasibility study

基于成像的痴呆诊断测试在中国市场的商业化——可行性研究

• 批准号: 10020217
• 金额: $ 2.67万
• 依托单位: AINOSTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10020217
• 关键词: Commercialisation; imaging; based; dementia; diagnostic

Despite rapidly increasing numbers of people living with dementia, there are substantial difficulties with diagnosis. Around a third of people living with dementia have not received a diagnosis. Even in people who are diagnosed, there is typically a delay of years between developing symptoms and receiving a diagnosis. These problems mean that people are not empowered by receiving information about what is causing their symptoms, and are unable to access treatments. The first treatment that could slow the progression of dementia has just been approved for use in the USA, making early and accurate diagnosis of dementia an urgent priority.One important reason for delayed and inaccurate dementia diagnosis is that the human eye is not reliably able to tell from brain scans who has early dementia, and who is likely to have a deterioration in their memory in the future. We propose to use artificial intelligence to derive this information from routine brain scans.AINOSTICS' technology represents a breakthrough that would provide an automated, and personalised healthcare platform for assisting the clinical diagnosis of dementia using multi-modal imaging and non-imaging data that are already routinely acquired in healthcare and research settings; useful for both the treatment of patients, and importantly, in the development of novel therapeutics.AINOSTICS' technology can automatically and intelligently analyse scans to provide sensitive and accurate micro-structural information about key tissue and organ structures then compare this with information from healthy populations to detect the signatures of disease. We intend for AINOSTICS' software to become a routine part of clinical practice and drug development as the results of our intelligent analysis will provide clinicians, researchers, and imaging centres a convenient and cost-effective means to get reliable, quantitative and objective diagnostic and prognostic data.For serious global diseases, AINOSTICS' technology has the potential to save time during patient assessments, accelerate clinical pathways, standardise the quality of care and improve patient outcomes in addition to making important contributions to the development of disease modifying therapeutics.

尽管患有痴呆症的人数迅速增加，但诊断仍有很大的困难。大约三分之一的痴呆症患者没有得到诊断。即使在被诊断的人中，在出现症状和接受诊断之间通常也会延迟数年。这些问题意味着人们无法获得有关导致其症状的信息，并且无法获得治疗。第一种可以减缓痴呆症进展的治疗方法刚刚在美国获得批准，这使得早期和准确诊断痴呆症成为当务之急。痴呆症诊断延迟和不准确的一个重要原因是，人眼无法可靠地从脑部扫描中分辨出谁患有早期痴呆症，以及谁可能在未来出现记忆力衰退。我们建议使用人工智能从常规脑部扫描中获取这些信息。AINOSTICS的技术代表了一项突破，将提供一个自动化、个性化的医疗保健平台，使用多模式成像和非成像数据来辅助痴呆症的临床诊断，这些数据已经在医疗保健和研究环境中常规获取;对患者的治疗有用，重要的是，AINOSTICS的技术可以自动和智能地分析扫描，以提供灵敏和准确的微然后，将关于关键组织和器官结构的结构信息与来自健康人群的信息进行比较，以检测疾病的特征。我们希望AINOSTICS的软件成为临床实践和药物开发的常规组成部分，因为我们的智能分析结果将为临床医生，研究人员和成像中心提供方便且具有成本效益的手段，以获得可靠，定量和客观的诊断和预后数据。对于严重的全球性疾病，AINOSTICS的技术有可能节省患者评估时间，加速临床路径，提高护理质量，改善患者预后，并为疾病修饰疗法的发展做出重要贡献。